The chemotherapy induced neutropenia market was valued at USD 651.26 Million in 2025 and is expected to grow at a CAGR of 3.58%, reaching USD 925.79 Million by 2035. The market is experiencing growth due to rising cancer prevalence and demand for supportive care medications.
Base Year
Historical Period
Forecast Period
Compound Annual Growth Rate
3.58%
Value in USD Million
2026-2035
*this image is indicative*
Chemotherapy is the treatment modality that is used to treat different types of cancers. Chemotherapy induced neutropenia is a common risk associated with cancer treatment where neutrophils (a type of white blood cells) have abnormally low counts, making patients susceptible to infections. The market is experiencing a rise in the volume of cancer patients receiving chemotherapy, with over 1 million people in the United States undergoing the treatment annually. Consequently, it is projected to fuel the chemotherapy induced neutropenia demand in the forecast period.
The surge in the approval of treatment products by the health authorities is poised to support the market expansion. In November 2023 , Evive Biotech (a subsidiary of Yifan Pharmaceutical Co., Ltd.) and Acrotech Biopharma (a wholly owned subsidiary of Aurobindo Pharma USA, Inc.) announced the approval of Efbemalenograstim alfa, marketed under the brand name Ryzneuta, by the United States Food and Drug Administration (FDA) to treat chemotherapy induced neutropenia in adult patients with non-myeloid malignancies. The medication developed by Evive Biotech is the first innovative biologics proven to stimulate the production of neutrophils. Acrotech Biopharma will be responsible for the commercialization of the product in the United States. The penetration of such effective treatment options is anticipated to boost the chemotherapy induced neutropenia market growth.
The market is also driven by the increased acquisition and merger initiatives by the key market players to meet the clinical needs of the patients suffering from chemotherapy induced neutropenia. Moreover, the rising patient awareness and the advancement in the healthcare system will accelerate the market value in coming years.
"Global Chemotherapy Induced Neutropenia Market Report and Forecast 2026-2035" offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Type
Based on drug types, the market is segmented into colony-stimulating factors (CSFs), granulocyte colony-stimulating factor (G-CSF), and granulocyte-macrophage colony-stimulating factor (GM-CSF). These drugs stimulate the production of white blood cells to prevent or treat neutropenia.
Market Breakup by Application
The chemotherapy induced neutropenia market report includes segmentation based on application as well. It includes breast cancer, lung cancer, colorectal cancer, ovarian cancer, and others. This market segment represents different types of cancers for which chemotherapy induced neutropenia treatments are utilized to manage or prevent complications.
Market Breakup by Distribution Channel
Distribution channels in the market are online pharmacies, retail pharmacies, hospital pharmacies, and others. The robust network of these channels caters to the diverse needs of the patients and contributes to the chemotherapy induced neutropenia market share.
Market Breakup by End User
End users of the market are cancer research institutes, hospitals, clinics, and other healthcare facilities.
Market Breakup by Region
Based on the region, the market includes the United States, EU-4 (Germany, France, Italy, Spain), United Kingdom, Japan, and China. North America dominates the market share which can be attributed to the high prevalence and incidence rates of cancer in the region. Furthermore, the presence of a well-established healthcare system also supports market growth in the market.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Upto 15% Off
USD
$3299 $2969
$5499 $4949
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market is anticipated to grow at a CAGR of 3.58% during the forecast period of 2026-2035, driven by the rising prevalence of cancer along with the growing demand for effective neutropenia management solutions across the 8 major markets.
The market demand is driven by rising patient awareness and investments to bring advancements in the healthcare system.
One of the significant trends in the market is the surge in the approval of treatment products by the health authorities. In November 2023 , Evive and Acrotech Biopharma announced the approval of Ryzneuta by the United States Food and Drug Administration (FDA) to treat chemotherapy induced neutropenia in adult patients with non-myeloid malignancies.
Based on the drug type, the market is segmented into colony-stimulating factors (CSFs), granulocyte colony-stimulating factor (G-CSF), and granulocyte-macrophage colony-stimulating factor (GM-CSF).
Major end users of the market are cancer research institutes, hospitals, clinics, and other healthcare facilities.
Distribution channels in the market include online pharmacies, retail pharmacies, hospital pharmacies, and others.
The market is segmented by application into breast cancer, lung cancer, colorectal cancer, ovarian cancer, among others.
The major regions of the market include the United States, EU-4 (Germany, France, Italy, Spain), United Kingdom, Japan, and China.
Key players involved in the market are Novartis AG, Lupin Limited, Ligand Pharmaceuticals, Biogenomics Limited, Baxter International, Apotex, Evive Biotech, BeyondSpring Pharmaceuticals, Myelo Therapeutics, Cellerant Therapeutics, Aileron Therapeutics, Enzychem Lifesciences Corporation, Spectrum Pharmaceuticals, G1 Therapeutics, and Teva B.V.
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Type |
|
| Breakup by Application |
|
| Breakup by Distribution Channel |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share